Financials Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:54:44 2024-07-09 pm EDT 5-day change 1st Jan Change
17.3 USD -0.75% Intraday chart for Pharvaris N.V. +2.40% -38.48%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 419.3 355.2 1,324 865.8 - -
Enterprise Value (EV) 1 210.2 193.3 933 596.4 734.3 451.7
P/E ratio -9.04 x -4.63 x -9.66 x -6.7 x -6.35 x -5.87 x
Yield - - - - - -
Capitalization / Revenue - - - - - 180 x
EV / Revenue - - - - - 93.8 x
EV / EBITDA -4.58 x -2.57 x -10.9 x -4.94 x -5.05 x -2.87 x
EV / FCF -4.7 x -2.87 x -10 x -4.14 x -4.01 x -2.19 x
FCF Yield -21.3% -34.8% -9.98% -24.1% -24.9% -45.6%
Price to Book 2.05 x 2.38 x 3.46 x 3.35 x 8.21 x 2.78 x
Nbr of stocks (in thousands) 33,129 33,788 52,109 53,817 - -
Reference price 2 12.66 10.51 25.41 16.09 16.09 16.09
Announcement Date 3/29/22 4/5/23 4/10/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - 4.817
EBITDA 1 - -23.41 -45.86 -75.21 -85.99 -120.7 -145.3 -157.6
EBIT 1 - -25.01 -54.14 -86.71 -96.91 -125 -145.4 -161.8
Operating Margin - - - - - - - -3,358.03%
Earnings before Tax (EBT) 1 - -26.07 - -75.65 -99.83 -128.9 -145.2 -163.7
Net income 1 -8.027 -26 -42.73 -76.33 -100.9 -123.7 -137.2 -163.7
Net margin - - - - - - - -3,397.75%
EPS 2 -1.660 -5.360 -1.400 -2.270 -2.630 -2.401 -2.532 -2.740
Free Cash Flow 1 - -21.54 -44.73 -67.29 -93.14 -144 -183 -206
FCF margin - - - - - - - -4,276.59%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 11/12/20 4/29/21 3/29/22 4/5/23 4/10/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - -
EBITDA - - -18.2 - - - - - -24.64 - - - -
EBIT 1 -16.24 -19.38 -21.38 -22.39 -23.57 -21.08 -22.46 -26.2 -27.18 -28.31 -30.15 -33.07 -34.71
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - - -9.88 -10.89 -38.89 - -21.8 -23.45 -32 -27.73 -30.42 -34.3 -36.56
Net income 1 -12.34 -16.03 -12.62 -8.5 -39.2 -22.63 -21.9 -23.6 -32.75 -28.02 -29.88 -32.14 -33.52
Net margin - - - - - - - - - - - - -
EPS 2 -0.0900 -0.4800 -0.3800 -0.2500 -1.160 -0.6700 -0.6300 -0.5800 -0.7600 -0.5200 -0.5578 -0.5918 -0.6158
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/29/22 5/11/22 9/12/22 12/8/22 4/5/23 5/8/23 8/7/23 11/2/23 4/10/24 5/8/24 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 98.6 209 162 391 269 132 414
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -21.5 -44.7 -67.3 -93.1 -144 -183 -206
ROE (net income / shareholders' equity) - -45.4% -28.4% -43.1% -37.8% -45.2% -83.9% -59.8%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 19.80 6.180 4.410 7.340 4.800 1.960 5.780
Cash Flow per Share 2 - -4.430 -1.470 -2.000 -2.420 -2.190 -2.210 -
Capex 1 - - 0.13 0.12 0.09 4.66 9.31 18.6
Capex / Sales - - - - - - - 386.72%
Announcement Date 11/12/20 4/29/21 3/29/22 4/5/23 4/10/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
16.09 EUR
Average target price
31.19 EUR
Spread / Average Target
+93.87%
Consensus
  1. Stock Market
  2. Equities
  3. PHVS Stock
  4. Financials Pharvaris N.V.